Summary
Patients with mild Alzheimer’s disease enrolled in EXPEDITION EXT had already received 80 weeks of treatment with either solanezumab or placebo. Utilizing a unique approach to the delayed-start model, researchers report that cognitive and instrumental function outcomes in delayed-start patients did not catch up to those in early-start patients, supporting the benefit of initiating treatment as early as possible.
- solanezumab
- Alzheimer’s disease
- delayed-start
- EXPEDITION EXT
- NCT01127633
- dementias
- neurology clinical trials
- © 2015 SAGE Publications